Surgery Partners, Inc. (SGRY) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Strong growth in orthopedic procedures and revenue guidance reaffirmation are positive. However, weaker-than-expected demand, a reduction in acquisition spending, and a $20 million EBITDA guidance cut are concerning. Management's uncertainty about macroeconomic factors and payer mix changes adds to the ambiguity. The market cap suggests moderate sensitivity, leading to a neutral prediction.
Key Financial Performance
Net Revenue $821.5 million, up 6.6% year-over-year. The increase is attributed to broad-based growth across specialties, particularly in gastrointestinal and MSK procedures, and overcoming the impact of divested facilities.
Adjusted EBITDA $136.4 million, up 6.1% year-over-year. The margin was 16.6%, essentially flat compared to last year. Growth was supported by cost discipline and reduced incentive-based compensation, offsetting inflationary pressures and weaker-than-expected volume and payer mix.
Same-Facility Revenue Growth 6.3% year-over-year. This includes same-facility case growth of 3.4% and rate growth of 2.8%. The growth reflects strong performance in high-acuity specialties like orthopedics.
Surgical Cases Over 166,000 cases performed in consolidated facilities, representing 2.1% growth year-over-year. Growth was driven by increases in gastrointestinal and MSK procedures, including joint-related surgeries.
Total Joint Surgeries in ASC Facilities 16% growth in the third quarter and 23% year-to-date compared to the same period last year. Growth was driven by investments in robotics and physician recruitment.
Payer Mix Commercial payers represented 50.6% of revenues, down 160 basis points year-over-year, while governmental sources, primarily Medicare, increased by 120 basis points. The shift is attributed to normal quarterly variability and softer-than-expected same-facility volume growth.
Operating Cash Flow $83.6 million for the third quarter. The cash flow was stable, with no unusual transactions other than changes in interest rates on corporate debt.
Capital Deployment for Acquisitions $71 million deployed year-to-date in 2025, adding several facilities at attractive multiples. Additionally, $50 million was generated from divestitures of 3 ASCs, which included $45 million in cash and $5 million in debt reduction.
Supply Costs 25.4% of net revenue, down 70 basis points year-over-year. The reduction is attributed to ongoing procurement and efficiency initiatives.
Salaries and Wages 29.6% of net revenue, flat compared to the prior year. This stability reflects disciplined cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Surgical cases: Performed over 166,000 surgical cases in Q3, with significant growth in GI and MSK procedures, particularly orthopedics. Total joint surgeries in ASC facilities grew 16% in Q3 and 23% year-to-date.
Robotics and physician recruitment: Invested in 74 surgical robots and recruited over 500 new physicians through September 30, 2025.
De novo facilities: Opened 2 new facilities in Q3, with 9 under construction and over a dozen in the development pipeline, focusing on high-acuity specialties like orthopedics.
M&A activity: Deployed $71 million for acquisitions in 2025 and divested 3 ASCs for $50 million in cash and debt reduction. Evaluating over $300 million in M&A opportunities.
Cost management: Achieved cost discipline with stable margins, reduced incentive-based compensation, and procurement efficiencies. Supply costs decreased by 70 basis points year-over-year.
Revenue cycle efficiencies: Continued improvements in revenue cycle operations to support margin expansion.
Portfolio optimization: Initiated a strategic review to divest or partner on larger surgical hospitals to reduce leverage and enhance cash flow. Active discussions on a small number of assets.
Guidance revision: Revised 2025 revenue guidance to $3.275-$3.3 billion and adjusted EBITDA to $535-$540 million due to delayed capital deployment and divestitures.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Same-facility volume growth: Softer-than-expected same-facility volume growth in recent months, trailing internal expectations and prompting adjustments to the fourth quarter outlook.
Payer mix changes: Commercial payers' revenue share decreased by 160 basis points year-over-year, while governmental sources increased by 120 basis points, potentially impacting revenue and profitability.
Delayed capital investments: Timing-related impacts of capital activity, including delayed capital investments and lost earnings from divested ASCs, have led to a revision in full-year guidance.
Construction and regulatory delays: Several recently opened de novo facilities have not reached breakeven as quickly as anticipated due to construction and regulatory approval delays, creating near-term pressure on earnings.
Economic uncertainties: Potential softness in surgical demand and payer mix, particularly among commercial patients, has led to a cautious outlook for the fourth quarter.
High capital intensity of certain facilities: Larger surgical hospitals under evaluation for divestiture are more capital intensive and carry higher levels of finance lease obligations, adversely impacting cash flow conversion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has revised its full-year revenue guidance to a range of $3.275 billion to $3.3 billion, reflecting timing-related impacts of capital activity and a cautious outlook for the fourth quarter.
Adjusted EBITDA Guidance for 2025: Adjusted EBITDA is now expected to be in the range of $535 million to $540 million, reflecting delayed capital deployment, lost earnings from divested ASCs, and a more cautious outlook on commercial payer mix and volume.
Same-Facility Revenue Growth: Same-facility revenue growth for the full year is expected to align with the midpoint of the long-term target range of 4% to 6%, reflecting a prudent approach to the fourth quarter.
Capital Deployment Outlook: The company has deployed $71 million for acquisitions in 2025 and anticipates deploying capital strategically in the months ahead, with a robust M&A pipeline of over $300 million in opportunities under active evaluation. A return to normal levels of annual capital investment is expected moving into 2026.
De Novo Facility Investments: The company has opened 2 new de novo facilities in the third quarter, with 9 under construction and more than a dozen in the development pipeline. These facilities are expected to be highly accretive and profitable in the long term, despite near-term pressures from construction and regulatory delays.
Portfolio Optimization: The company is actively evaluating the divestiture or partnership of larger surgical hospitals to enhance flexibility, reduce leverage, and increase cash flow conversion. Updates on this initiative will be provided in spring 2026.
2026 Planning and Outlook: The company is monitoring recent shifts in surgical demand and payer mix and will factor these dynamics into its 2026 planning, which will be reviewed during the Q4 2025 call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What caused the weakness in demand or procedure volumes in Q3 and expectations for Q4?
A:The weakness in Q3 was broad-based, with higher government payer mix and softer growth than expected. Management does not attribute it to any specific specialty or geography and is uncertain if macroeconomic factors are involved. They expect growth in Q4 but below internal expectations.
Q:Why has there been a pullback in acquisition spending?
A:The pullback is due to deal timing and disciplined decision-making. Management remains encouraged by the pipeline and expects to return to normal M&A flow in the future.
Q:Is the weaker commercial volume growth related to payer denials or rate updates?
A:No, management does not see systematic differences in payer denials or rate updates. The weaker commercial growth trend is not as strong as expected but still positive.
Q:What is the breakdown of the $20 million EBITDA guidance cut?
A:Approximately 60% of the $20 million cut is related to development or capital timing issues, such as acquisitions and divestitures. The remaining 40% is due to a slight change in payer mix trends observed in Q3 and Q4.
Q:What is the status of de novo facility development and its impact?
A:De novo facilities are progressing, with double-digit developments expected. Delays are due to construction and regulatory issues, not volume pressures. These facilities are seen as accretive and strategically important for growth.
Q:Has patient behavior around deductible resets changed due to higher costs?
A:Management is uncertain about changes in patient behavior related to deductible resets. They are monitoring trends but have not observed significant changes.
Q:What is the progress on the portfolio review process?
A:Management is focused on optimizing the portfolio by divesting or partnering in markets that are less aligned with their short-stay surgery ethos. They aim to accelerate free cash flow and deleveraging but did not provide specific market details.
Q:Are there any headwinds or tailwinds expected for 2026?
A:Management is monitoring payer mix trends but does not see systemic issues. They plan to provide more details during the Q4 call.
Q:What is the impact of new surgeon recruitment on growth?
A:Over 500 physicians have been recruited year-to-date, with a focus on high-acuity procedures like orthopedics. New surgeons typically double their business in year 2, contributing to growth.
Q:What is the status of ophthalmology growth?
A:Ophthalmology growth is positive on a same-facility basis but lower than the overall growth algorithm. Some pressure points include retirements and short-term leaves.
Q:What criteria are used for divestitures?
A:Divestitures focus on facilities that can accelerate deleveraging and free cash flow. Management evaluates market-specific opportunities and considers partnerships or sales.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about potential systemic issues in payer mix trends and changes in patient behavior related to deductible resets. They also provided limited details on specific markets or facilities involved in the portfolio review process.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASC divestiture
ASC facility
ASCs enterprise
Day spring
Day update
Dr distinction
Instructions conference
Investor Day
Margin cost
Medicare basis
Today color
Today impact
Volume GI
ability capital
ability dynamic
access
capital investment
conversion
deployment date
discussion
evaluation
impact capital
moment
opening
optimization effort
outlook remainder
payer mix
physician recruitment
portfolio optimization
proceeds
review
shareholder value
term value
value creation
SGRY Transcript
Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript
Positive5-5
The company reported strong financial performance with a 12% revenue increase and a 25% net income growth. Despite risks mentioned in forward-looking statements, the absence of negative details in the Q&A suggests no major concerns from analysts. The market cap indicates a moderate reaction, leading to a positive stock price movement prediction.
Surgery Partners, Inc. (SGRY) Presents at Barclays 28th Annual Global Healthcare Conference Prepared Remarks Transcript
Neutral3-10
Surgery Partners, Inc. (SGRY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Surgery Partners, Inc. (SGRY) Q4 2025 Earnings Call Transcript
Unknown3-3
The earnings call presents a mixed picture. Positive elements include strategic M&A plans, new facility investments, and a share buyback program, indicating confidence. However, challenges such as payer mix issues, slow revenue growth, and cautious guidance offset these positives. The Q&A reveals management's plans to address these challenges, but uncertainty remains. Given the company's market cap and the balance of positive and negative factors, the stock price is likely to remain stable in the short term, resulting in a neutral rating.
SGRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
